Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Foghorn Therapeutics (FHTX) Cash from Investing Activities: 2019-2024

Historic Cash from Investing Activities for Foghorn Therapeutics (FHTX) over the last 6 years, with Dec 2024 value amounting to -$29.9 million.

  • Foghorn Therapeutics' Cash from Investing Activities rose 158.02% to $35.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $121.1 million, marking a year-over-year increase of 917.68%. This contributed to the annual value of -$29.9 million for FY2024, which is 120.70% down from last year.
  • According to the latest figures from FY2024, Foghorn Therapeutics' Cash from Investing Activities is -$29.9 million, which was down 120.70% from $144.4 million recorded in FY2023.
  • In the past 5 years, Foghorn Therapeutics' Cash from Investing Activities ranged from a high of $144.4 million in FY2023 and a low of -$244.3 million during FY2022.
  • Moreover, its 3-year median value for Cash from Investing Activities was -$29.9 million (2024), whereas its average is -$43.3 million.
  • As far as peak fluctuations go, Foghorn Therapeutics' Cash from Investing Activities crashed by 11,198.13% in 2020, and later surged by 159.12% in 2023.
  • Yearly analysis of 5 years shows Foghorn Therapeutics' Cash from Investing Activities stood at -$108.9 million in 2020, then soared by 133.21% to $36.2 million in 2021, then tumbled by 775.43% to -$244.3 million in 2022, then soared by 159.12% to $144.4 million in 2023, then slumped by 120.70% to -$29.9 million in 2024.